Javascript must be enabled to continue!
423. POSTOPERATIVE SKELETAL MUSCLE MASS IN ESOPHAGEAL CANCER SURGERY PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY
View through CrossRef
Abstract
Recently, the significant decrease in skeletal muscle mass after esophagectomy in patients who underwent neoadjuvant chemotherapy, which in turn has been reported to affect long-term survival. The results of JCOG1109 have been published, and while DCF has become the standard of care as neoadjuvant chemotherapy, its toxicity has also been pointed out. In this study, we analyzed the relationship between changes in body composition before and after neoadjuvant chemotherapy and postoperative complications after esophagectomy.
Among esophageal cancer patients who underwent esophagectomy after preoperative chemotherapy from September 2018 to May 2020, 74 patients were included, excluding patients with recurrence within 1 year after surgery and patients with gastrointestinal fistula. The relationship between body composition and postoperative complications, and changes in body weight and skeletal muscle mass were analyzed.
The male-to-female ratio was 60:14, and the median age was 65.0 years. When the subjects were divided into DCF and Others, there was a significant difference in skeletal muscle loss in the Others group. There was no significant difference in the incidence of postoperative complications by chemotherapy, nor an incidence of postoperative complications between the DCF and Others. There was no significant difference in weight loss between the DCF group and the Others group, but a significant decrease in skeletal muscle mass in the DCF group at one year. The decrease up to 4 months after surgery was particularly large.
In the present analysis, DCF therapy as preoperative treatment had no effect on the occurrence of postoperative complications, but was associated with a long-term decrease in skeletal muscle mass, suggesting that the toxicity of DCF therapy may have a long-term effect. Although the tumor suppression effect of preoperative treatment was proven, long-term nutritional and rehabilitative interventions were considered necessary to establish a truly favorable long-term prognosis for the patients.
Title: 423. POSTOPERATIVE SKELETAL MUSCLE MASS IN ESOPHAGEAL CANCER SURGERY PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY
Description:
Abstract
Recently, the significant decrease in skeletal muscle mass after esophagectomy in patients who underwent neoadjuvant chemotherapy, which in turn has been reported to affect long-term survival.
The results of JCOG1109 have been published, and while DCF has become the standard of care as neoadjuvant chemotherapy, its toxicity has also been pointed out.
In this study, we analyzed the relationship between changes in body composition before and after neoadjuvant chemotherapy and postoperative complications after esophagectomy.
Among esophageal cancer patients who underwent esophagectomy after preoperative chemotherapy from September 2018 to May 2020, 74 patients were included, excluding patients with recurrence within 1 year after surgery and patients with gastrointestinal fistula.
The relationship between body composition and postoperative complications, and changes in body weight and skeletal muscle mass were analyzed.
The male-to-female ratio was 60:14, and the median age was 65.
0 years.
When the subjects were divided into DCF and Others, there was a significant difference in skeletal muscle loss in the Others group.
There was no significant difference in the incidence of postoperative complications by chemotherapy, nor an incidence of postoperative complications between the DCF and Others.
There was no significant difference in weight loss between the DCF group and the Others group, but a significant decrease in skeletal muscle mass in the DCF group at one year.
The decrease up to 4 months after surgery was particularly large.
In the present analysis, DCF therapy as preoperative treatment had no effect on the occurrence of postoperative complications, but was associated with a long-term decrease in skeletal muscle mass, suggesting that the toxicity of DCF therapy may have a long-term effect.
Although the tumor suppression effect of preoperative treatment was proven, long-term nutritional and rehabilitative interventions were considered necessary to establish a truly favorable long-term prognosis for the patients.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Objectives:
Anterior cruciate ligament (ACL) reconstruction is the 6th most common orthopedic procedure performed in the United States (1,2). There is substanti...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...

